Aldosterone antagonists for preventing the progression of chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Navaneethan, Sankar D ^a   Nigwekar, Sagar U ^b   Sehgal, Ashwini R ^c   Strippoli, Giovanni F M ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; PLACEBO; POTASSIUM;

ALBUMINURIA; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; REVIEW;

EID: 70049108525     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007004.pub2     Document Type: Review

References (51)

1. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International 2006;70(12):2116-2123 [MEDLINE: 17035949] (Pubitemid 44871374)
2. Bianchi S, Bigazzi R, Campese VM. Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [Abstract]. Journal of the American Society of Nephrology 2006;17 (Abstracts):33A. [CENTRAL: CN-00615828]
3. Chrysostomou A, Pedagogos E, Briganti E, Becker GJ. A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [Abstract]. Nephrology 2005;10(Suppl):A137. [CENTRAL: CN-00602127]
4. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN 2006;1(2):256-262 [MEDLINE: 17699214]
5. Epstein M, Buckalew V, Martinez F. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract]. American Journal of Hypertension 2002;15(4 Suppl 1):24A.
6. Epstein M, Weinberger M, Lewin A, Martinez F, He W, Krause S. The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [Abstract]. Journal of the American Society of Nephrology 2003;14(Nov):6A. [CENTRAL: CN-00550622]
7. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al.Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN 2006;1(5):940-951 [MEDLINE: 17699311]
8. * Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al.Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research 2008;31(1):59-67. [MEDLINE: 18360019]
9. Furumatsu Y, Shoji T, Hayashi D, Tomida K, Kaneko T, Tsubakihara Y, et al.Antiproteiuric effect of triple blockade with angiotensin-converting- enzyme inhibitor, angiotensin-II receptor blocker and spironolactone; One year follow up. [Abstract]. Journal of the American Society of Nephrology 2004;15:58A. [CENTRAL: CN-00653797]
10. Furumatsu Y, Shoji T, Tomida K, Mikami S, Kaneko T, Togawa M, et al.Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone. [Abstract]. Journal of the American Society of Nephrology 2003;14:762A. [CENTRAL: CN-00653796]
11. van denMeiracker AH, Baggen RG, Pauli S. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. Journal of Hypertension 2006;24(11):2285-2292 [MEDLINE: 17053552]
12. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005;28(9):2106-2112 [MEDLINE: 16123474] (Pubitemid 41242452)
13. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Parving HH. Beneficial impact of spironolactone in diabetic nephropathy. Kidney International 2005;68(6):2829-2836 [MEDLINE: 16316360] (Pubitemid 43251030)
14. Schjoedt KJ, Rossing K, Tarnow L, Parving H. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [Abstract]. Journal of the American Society of Nephrology 2005;16:57A.
15. Schjoedt KJ, Rossing K, Juhl TR. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International 2006;70(3):536-542 [MEDLINE: 16775595] (Pubitemid 44141580)
16. Larczynski W, Tylicki L, Rutkowski P, Renke M, Rutkowski B. The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [Abstract]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742]
17. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, et al.Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases 2008;52(3):486-493 [MEDLINE: 18423812]
18. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International 2007;72(9):1164-1165 [MEDLINE: 17943159] (Pubitemid 47609048)
19. Retraction. Diabetic Medicine 2006;23:818.
20. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, et al.The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabetic Medicine 2004;21(5):471-475 [MEDLINE: 15089793] (Pubitemid 38608536)
21. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. Journal of the American Society of Nephrology 2005;16(11):3306-3314 [MEDLINE: 16192423] (Pubitemid 46187550)
22. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. American Journal of Kidney Diseases 2008;51(2):199-211. [MEDLINE: 18215698]
23. Brenner BM, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parving HH, et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001;345(12):861-869 [MEDLINE: 11565518]
24. Brenner B. Retarding the progression of renal disease. Kidney International 2003;64(1):370-378 [MEDLINE: 12787440]
25. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al.Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-2047 [MEDLINE: 17986697] (Pubitemid 47080496)
26. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-1291 [MEDLINE: 7718048] (Pubitemid 24340510)
27. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349(9069):1857-1863 [MEDLINE: 9217756]
28. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrology Dialysis Transplantation 2005;20(12):2587-2593 [MEDLINE: 16204281]
29. Greene EL, Kren S, Hostetter TH.Role of aldosterone in the remnant kidney model in the rat. Journal of Clinical Investigation 1996;98(4):1063-1068 [MEDLINE: 8770880] (Pubitemid 26293326)
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560 [MEDLINE: 12958120]
31. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. Journal of the American Society of Nephrology 2003;14(9):2395-2401 [MEDLINE: 12937319]
32. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al.Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine 2001;135(2):73-87. [MEDLINE: 11453706] (Pubitemid 32661190)
33. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al.Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine 2004;351(6):543-551 [MEDLINE: 15295047] (Pubitemid 39025171)
34. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. New England Journal of Medicine 1994; 330(13):877-884 [MEDLINE: 8114857]
35. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia). 1996.
36. United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed April 2009).
37. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999;319(7201):24-25 [MEDLINE: 10390455] (Pubitemid 29304341)
38. Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, et al.Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. American Journal of Physiology - Renal Physiology 2008;294(3):F628-37. [MEDLINE: 18094029]
39. ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008;358(15):1547-1559 [MEDLINE: 18378520]
40. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Archives of Internal Medicine 2007;167(18):1930- 1936 [MEDLINE: 17923591] (Pubitemid 47606631)
41. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al.The effect of spironolactone onmorbidity andmortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 1999;341(10):709-717 [MEDLINE: 10471456]
42. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 2003;348(14):1309-1321 [MEDLINE: 12668699] (Pubitemid 36384098)
43. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al.Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney International 2004;65(6):2309-2320 [MEDLINE: 15149345] (Pubitemid 38670018)
44. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31(1 Pt 2):451-458 [MEDLINE: 9453344] (Pubitemid 28124757)
45. Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney International 2003;64(6):1947-1955 [MEDLINE: 14633117]
46. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al.Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. Journal of Biological Chemistry 1998;273(9):4883-4891 [MEDLINE: 9478930] (Pubitemid 28108638)
47. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology 1981;91(3):457-465 [MEDLINE: 7035596] (Pubitemid 12203819)
48. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. Journal of the American Society of Nephrology 2005;16(10):3081-3091 [MEDLINE: 16135776] (Pubitemid 44743506)
49. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006257] (Pubitemid 46841144)
50. Navaneethan SD, Nigwekar SU, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD007004]
51. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(3):542-551 [MEDLINE: 19261819]